Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
286 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016', provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) - The report reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects - The report assesses Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9 Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17 Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 4SC AG 21 AbbVie Inc. 22 Arno Therapeutics, Inc. 23 Astellas Pharma Inc. 24 Astex Pharmaceuticals, Inc. 25 AstraZeneca Plc 26 Boehringer Ingelheim GmbH 27 Bristol-Myers Squibb Company 28 Celgene Corporation 29 Cellular Biomedicine Group, Inc. 30 F. Hoffmann-La Roche Ltd. 31 Hutchison MediPharma Limited 32 ImmunoGen, Inc. 33 Immunomedics, Inc. 34 Incyte Corporation 35 Infinity Pharmaceuticals, Inc. 36 Innate Pharma S.A. 37 Juno Therapeutics Inc. 38 Karyopharm Therapeutics, Inc. 39 Les Laboratoires Servier SAS 40 LFB S.A. 41 Lymphocyte Activation Technologies, S.A. 42 Medicenna Therapeutics, Inc. 43 Millennium Pharmaceuticals, Inc. 44 MorphoSys AG 45 Novartis AG 46 Oncternal Therapeutics, Inc. 47 Ono Pharmaceutical Co., Ltd. 48 Portola Pharmaceuticals, Inc. 49 Sanofi 50 TG Therapeutics, Inc. 51 Threshold Pharmaceuticals, Inc. 52 Tragara Pharmaceuticals, Inc. 53 Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Combination Products 55 Assessment by Target 56 Assessment by Mechanism of Action 59 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 (INCB-039110 + INCB-040093) - Drug Profile 66 4SC-202 - Drug Profile 67 acalabrutinib - Drug Profile 69 ACP-319 - Drug Profile 72 afuresertib hydrochloride - Drug Profile 73 AGS-67E - Drug Profile 76 AR-42 - Drug Profile 78 AT-7519 - Drug Profile 80 AZD-6738 - Drug Profile 83 BI-836826 - Drug Profile 85 BMS-986016 - Drug Profile 87 buparlisib hydrochloride - Drug Profile 88 CBM-C19.1 - Drug Profile 92 CBM-C20.1 - Drug Profile 93 CC-122 - Drug Profile 95 Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile 97 Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 98 cerdulatinib - Drug Profile 99 duvelisib - Drug Profile 101 evofosfamide - Drug Profile 104 HMPL-523 - Drug Profile 112 IMGN-529 - Drug Profile 113 IMMU-114 - Drug Profile 115 JCAR-014 - Drug Profile 116 JCAR-015 - Drug Profile 117 lirilumab - Drug Profile 119 MDNA-56 - Drug Profile 121 monalizumab - Drug Profile 122 MOR-208 - Drug Profile 124 nivolumab - Drug Profile 126 obinutuzumab - Drug Profile 134 pilaralisib - Drug Profile 138 S-055746 - Drug Profile 141 selinexor - Drug Profile 142 spebrutinib besylate - Drug Profile 148 TAK-659 - Drug Profile 150 TG-02 - Drug Profile 151 TGR-1202 - Drug Profile 154 tisagenlecleucel-T - Drug Profile 157 ublituximab - Drug Profile 160 UC-961 - Drug Profile 163 ulocuplumab - Drug Profile 164 urelumab - Drug Profile 166 venetoclax - Drug Profile 168 Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 172 Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 271 Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 273 Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 274 Featured News & Press Releases 274 Appendix 282 Methodology 282 Coverage 282 Secondary Research 282 Primary Research 282 Expert Panel Validation 282 Contact Us 282 Disclaimer 283
List of Tables
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2016 12 Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016 24 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016 25 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2016 26 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016 27 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 28 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016 29 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 30 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016 31 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016 32 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 33 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 34 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016 35 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016 36 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016 37 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016 38 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 39 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016 40 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016 41 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 42 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016 43 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016 44 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 45 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H1 2016 46 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 47 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016 48 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016 49 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016 50 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 51 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 52 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016 53 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016 54 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 55 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 56 Assessment by Monotherapy Products, H1 2016 57 Assessment by Combination Products, H1 2016 58 Number of Products by Stage and Target, H1 2016 60 Number of Products by Stage and Mechanism of Action, H1 2016 63 Number of Products by Stage and Route of Administration, H1 2016 66 Number of Products by Stage and Molecule Type, H1 2016 68 Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016 175 Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016 274 Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2016 275 Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016 276
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
